Clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases.

Sectors
Healthcare
Life Sciences
First Invested
2017
Public/PIPES
Company Status
Acquired
Acquired by Novartis AG
Associated Team
Lulu Xu
Paul Walker
NEA Portfolio: Regulus Therapeutics